Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population
Paul G. Richardson(Harvard University), Joan Bladé(Hospital Clínic de Barcelona), Alessandra Larocca(Cornell University), María‐Victoria Mateos(Hospital Clínico San Carlos), Agne Paner(Rush University Medical Center), Adrían Alegre(Hospital Universitario de La Princesa), Johan Harmenberg(Oncopeptides (Sweden)), Xavier Leleu(Inserm), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Sara Thuresson(Oncopeptides (Sweden)), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Catriona Byrne(Oncopeptides (Sweden)), Hanan Zubair(Oncopeptides (Sweden)), Christopher Maisel(Baylor Medical Center at Garland), Amitabha Mazumder(NYU Langone Health), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 3
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k